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Improving survival in salivary duct cancer with adjuvant 
androgen deprivation therapy
Wim van Boxtel and Carla van Herpen
Salivary gland cancer is a rare cancer, with a 
global annual incidence of 0.4–2.6/100.000 people [1]. 
Salivary duct carcinoma (SDC) is an aggressive subtype 
and represents 9% of salivary malignancies [1]. Median 
overall survival (OS) of SDC patients is 3–5 years after 
primary diagnosis [2]. In recurrent and/or metastatic SDC, 
androgen deprivation therapy (ADT) is first line palliative 
treatment in most patients, as 67–96% of SDCs is 
androgen receptor-positive (AR+) and an overall response 
rate of 42% was found in a recently conducted prospective 
phase 2 trial [3]. We studied as first the added value of 
adjuvant ADT for poor-risk AR+ SDC patients [4].
In a retrospective cohort study, 22 patients with 
stage 4a (T4a and/or N2 and M0) AR+ SDC were treated 
with adjuvant ADT, i.e. bicalutamide, a luteinizing 
hormone-releasing hormone (LHRH)-analogue or a 
combination of both after regular curative treatment. This 
consisted of a tumor resection in all cases, and a neck 
dissection and postoperative radiotherapy in most cases. 
Patients were treated in the Radboud university medical 
center (Nijmegen, the Netherlands) and the Istituto 
Nazionale dei Tumori (Milan, Italy). Disease free survival 
(DFS) and OS data were compared to a control group of 
111 stage 4a SDC patients that received regular curative 
treatment only. After a median follow-up of 20 months 
in the ADT-treated patients and 26 months in the control 
group, the 3-year DFS was estimated as 48.2% (95% 
confidence interval [CI] 14.0–82.4%) and 27.7% (95% 
CI 18.5–36.9%), respectively (P = 0.037). Three-year 
OS was 77.9% (95% CI 49.7–100%) and 53.9% (95% CI 
43.5–64.3%), respectively (P = 0.074). See Figure 1.
A univariable and multivariable Cox regression 
analysis was performed to correct for potential bias. In the 
univariable analysis, adjuvant ADT treated patients showed 
a hazard ratio of 0.49 (95% CI 0.21–1.14, P = 0.098) for 
DFS and 0.41 (95% CI 0.13–1.33, P = 0.137) for OS. In 
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Figure 1: Kaplan-Meier survival curves of the overall survival of adjuvant androgen deprivation therapy-treated 
patients (red) and the control group (blue) (P = 0.074). After correcting for confounders in a multivariable Cox regression 
analysis, a significant decreased hazard ratio of 0.06 (95% confidence interval 0.01-0.76, P = 0.03) was found.
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the multivariable analysis, we corrected for the following 
potential confounders: gender, age, treatment centre, location 
of primary tumor, T-stage, N-stage, ex pleomorphic adenoma 
(yes/no), resection margins, number of positive lymph nodes, 
postoperative radiotherapy (yes/no), adjuvant chemotherapy 
(yes/no), AR-status and year of diagnosis. This resulted in 
a significantly decreased hazard ratio for the adjuvant ADT 
treated patients of 0.14 (95% CI 0.03–0.75, P = 0.022) 
for DFS and 0.06 (95% CI 0.01–0.76, P = 0.030) for OS, 
compared to the control group. 
Several questions remain. Firstly, the optimal 
treatment regimen is unknown. In our study AR+ SDC 
patients were treated with bicalutamide monotherapy, a 
LHRH-analogue, or a combination of both. In prostate 
cancer, combined androgen blockade shows a modest 
increase in OS but diminished quality of life [5]. In SDC, 
no head-to-head comparison has been performed [6, 7]. 
Novel anti-androgens such as enzalutamide or the CYP17-
inhibitor abirateron could be an option for future adjuvant 
studies. Secondly, the optimal duration of treatment is 
not obvious. The planned treatment duration in our study 
differed from 1 to 5 years, but numbers were too small 
to determine the optimal duration. Finally, the efficacy of 
ADT in female AR+ SDC patients is of interest. In the 
palliative setting, there is no reason to presume diminished 
efficacy, although numbers of treated women is limited. In 
the adjuvant study, 3 of 22 adjuvant ADT-treated patients 
were women. They had no evidence of disease after 1, 3 
and 14 months of follow-up.
Understanding the mechanisms of primary treatment 
resistance of ADT in AR+ SDC will be important to predict 
response and benefit of treatment. Possible mechanisms 
include low or heterogeneous AR-expression, expression 
of AR-splice variants such as AR-V7, intratumoral 
androgen synthesis, [8] and interleukin-23 produced 
by myeloid-derived suppressor cells [9]. Functional 
inactivity of the AR-pathway, based on interpretation of 
mRNA expression of AR target genes, is another potential 
mechanism [10]. Finally, primary treatment resistance may 
be caused by activity of other tumor-driving pathways, 
for instance because of ERBB2 (encoding HER2) 
amplification or tumor-driving mutations. 
Before adopting adjuvant ADT into routine 
practice for poor-risk SDC patients, our results require 
confirmation, ideally in a prospective trial. However, due 
to the rarity of AR+ SDC running a phase III trial is not a 
real option. Therefore, registration all SDC patients, tumor 
characteristics, and treatment outcomes in a real-world 
registry is in our opinion the best way to learn from every 
patient and thereby improve prognosis of patients rapidly. 
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